Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes - Report - MDSpire

Evaluating Disability Progression in Multiple Sclerosis Through Patient-Reported Outcomes and Self-Administered Neuroperformance Metrics, Excluding Relapse Activity

  • By

  • Evy M. Reinders

  • Ariadna Masot-Llima

  • Susana Otero-Romero

  • René Carvajal

  • Álvaro Cobo-Calvo

  • Pere Carbonell-Mirabent

  • Jordina Beltran

  • Maria Jesús Arévalo

  • Helena Ariño

  • Georgina Arrambide

  • Cristina Auger

  • Luca Bollo

  • Joaquín Castilló

  • Manuel Comabella

  • Ingrid Galán

  • Alexis García-Sarreón

  • Andrew Goodman

  • Carrie M. Hersh

  • Delon La Puma

  • Le H. Hua

  • Luciana Midaglia

  • Neus Mongay-Ochoa

  • Ellen M. Mowry

  • Agustín Pappolla

  • Breogán Rodríguez-Acevedo

  • Jordi Río

  • Paula Tagliani

  • Ángela Vidal-Jordana

  • Andreu Vilaseca

  • Ana Zabalza

  • Deborah Pareto

  • Carlos Nos

  • Menno Schoonheim

  • Eva Strijbis

  • Jaume Sastre-Garriga

  • Madalina Tivarus

  • Tjalf Ziemssen

  • Àlex Rovira

  • Xavier Montalban

  • Mar Tintoré

  • Carmen Tur

  • July 6, 2026

Share

Evaluating Disability Progression in Multiple Sclerosis Through Patient-Reported Outcomes

Overview

This study investigates the ability of patient-reported outcomes (PROs) and self-administered neuroperformance tests to define disability worsening and progression independent of relapses in multiple sclerosis (MS). It highlights the prevalence of disability worsening and progression independent of relapse activity (PIRA) using a self-reported disability measure and self-administered tests.

Background

Disability accumulation in MS can occur through relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). PIRA can manifest early in the disease and is linked to unfavorable long-term outcomes.

Data Highlights

This study utilized real-world data from the MS PATHS network, analyzing the prevalence of disability worsening and PIRA through self-reported measures and their association with clinician-determined definitions.

Key Findings

  • PIRA can occur early in both relapsing and progressive MS phenotypes.
  • Patient-reported outcomes and self-administered tests may serve as practical tools for detecting disability worsening.
  • EDSS primarily reflects walking ability and may not capture clinical progression in other domains.
  • Self-reported measures like PDDS show a high correlation with EDSS but may have limitations at milder disability levels.

Clinical Implications

Incorporating PROs and self-administered tests into clinical practice may enhance the detection of disability worsening in MS.

Conclusion

The study emphasizes the potential of PROs and self-administered tests in identifying disability progression in MS.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis | Neurology
  6. 2024 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis - ScienceDirect
  7. Evaluation of a self-administered iPad®-based processing speed assessment for people with multiple sclerosis in a clinical routine setting | Journal of Neurology | Springer Nature Link
  8. Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis | Neurology
  9. 2024 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis - ScienceDirect
  10. Evaluation of a self-administered iPad®-based processing speed assessment for people with multiple sclerosis in a clinical routine setting | Journal of Neurology | Springer Nature Link

Original Source(s)

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes

  • by Evy M. Reinders, Ariadna Masot-Llima, Susana Otero-Romero, René Carvajal, Álvaro Cobo-Calvo, Pere Carbonell-Mirabent, Jordina Beltran, Maria Jesús Arévalo, Helena Ariño, Georgina Arrambide, Cristina Auger, Luca Bollo, Joaquín Castilló, Manuel Comabella, Ingrid Galán, Alexis García-Sarreón, Andrew Goodman, Carrie M. Hersh, Delon La Puma, Le H. Hua, Luciana Midaglia, Neus Mongay-Ochoa, Ellen M. Mowry, Agustín Pappolla, Breogán Rodríguez-Acevedo, Jordi Río, Paula Tagliani, Ángela Vidal-Jordana, Andreu Vilaseca, Ana Zabalza, Deborah Pareto, Carlos Nos, Menno Schoonheim, Eva Strijbis, Jaume Sastre-Garriga, Madalina Tivarus, Tjalf Ziemssen, Àlex Rovira, Xavier Montalban, Mar Tintoré, Carmen Tur

  • July 6, 2026

Related Content

Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing–remitting multiple sclerosis: a case–control study

Editorial: Host-microbe immunometabolic chat: a new era of organismal communication

Applications of dynamic gratings in neuro-ophthalmic disorders